Volume 5, Number 3—June 1999
Yellow Fever Vaccine
To the Editor: Monath et al. (1) outlined existing facilities for distribution of yellow fever vaccines in the United States and pointed to difficulties for prospective vaccinees in remote locations. Their recommendation that primary health-care providers be allowed to dispense yellow fever vaccination merits serious consideration. Acceptance of such a strategy in the United States would inevitably be emulated elsewhere. Nevertheless, before such a strategy is approved, vaccine potency should be monitored at distribution points, and a sample of vaccine recipients should be examined for vaccine-induced immune response.
In Nigeria, systematic investigation of yellow fever vaccine distribution and transportation to remote locations has found loss in vaccine potency. Vaccine in storage sites and immunization centers in Lagos was fully potent, but potency in Osun and Oyo was 016 log10 to 0.22 log10 lower than the stipulated level (2). Furthermore, the titer of two vaccine lots that had been frozen after reconstitution from their lyophilized state dropped from the initial 3.15 log10 to 3.53 log10 to zero.
If the United States were to implement an extended strategy, similar studies of vaccine lots should be conducted to determine whether every vaccinee has received a full dose of yellow fever vaccine. In Illinois during the early 1970s, weak links in maintenance of refrigeration facilities and use of outdated vaccines in vials exposed to the sun for long hours were reported for live poliovirus vaccines (3). In the Northern Territory of Australia, examination of 144 vials of hepatitis B vaccine formulations during transport to immunization centers showed that 47.5% had been exposed to temperatures of -3°C or lower (4).
Assays of the potency of yellow fever vaccine, as well as quantification of vaccine-induced neutralizing antibody, is a multistep procedure that relies on inoculation of mice or Vero or polysaccharide cells (5). The successful "take" of yellow fever vaccine can be determined starting the second postvaccination day by demonstrable viremia detected by reverse-transcriptase polymerase chain reaction and by marked increases in neopterin, beta2-microglobulin, and circulating CD8+ cells (6). Alternatively, elevated levels of tumor necrosis factor and interleukin-1 receptor antagonists on day two after vaccination (7) could be used to monitor the success of vaccinations by primary-care providers in remote areas in the United States (1) and elsewhere.
During the 1990s, isolation of yellow fever virus was reported in persons with a nonspecific febrile illness that did not meet the case definition of yellow fever (8). Air travel by such persons to the United States, which has areas infested by Aedes aegypti, could initiate yellow fever epidemics; because these travelers would have a nonspecific febrile illness, they would escape the existing surveillance network.
In conclusion, introducing yellow fever immunizations by primary health-care providers would be ideal, only with a concurrent plan to monitor vaccine potency at immunization centers and obtain in vitro evidence of a successful vaccine take. Such a strategy would blunt yellow fever–associated deaths, illnesses, and symptomless viral carriage in the community.
- Monath TP, Giesberg JA, Fierros EG. Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerg Infect Dis. 1998;4:698–702.
- Adu FD, Adedeji AA, Esan JS, Odusanya OG. Live viral vaccine potency: an index for assessing the cold chain system. Public Health. 1996;110:325–30.
- Rasmussen CM, Thomas CW, Mulrooney RJ, Morrissey RA. Inadequate poliovirus immunity levels in immunised Illinois children. Am J Dis Child. 1973;126:465–9.
- Miller NC, Harris MF. Are childhood immunization programmes in Australia at risk? Investigations of the cold chain in the Northern Territory. Bull World Health Organ. 1994;72:401–8.
- World Health Organization. Techniques for potency evaluation of yellow fever vaccine. Technical Report Series 1998;872:67-8.
- Reinhardt B, Jaspert R, Niedrig M, Kostner C. L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56:159–67.
- Hacker UT, Jelinek T, Erhardt S, Eigier A, Hartmann G, Nothdurft HD, In vivo syntheses of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis. 1998;177:774–8.
- Sanders EJ, Maffin AA, Tukei PM, Kuria G, Ademba G, Agata NN, First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. Am J Trop Med Hyg. 1998;59:644–9.
Suggested citation: Arya SC. Yellow Fever Vaccine [letter]. Emerg Infect Dis [serial on the Internet]. 1999, Jun [date cited]. Available from http://wwwnc.cdc.gov/eid/article/5/3/99-0333
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: December 13, 2010
- Page last updated: December 13, 2010
- Page last reviewed: December 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)